Clinical activity of <scp>CC‐90011</scp> , an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies-Reference-Cited by-同舟云学术

Clinical activity of CC‐90011 , an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies

Published:2022-06-23 Issue:17 Volume:128 Page:3185-3195
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hollebecque Antoine¹^ORCID,Salvagni Stefania²,Plummer Ruth³,Niccoli Patricia⁴,Capdevila Jaume⁵^ORCID,Curigliano Giuseppe⁶^ORCID,Moreno Victor⁷^ORCID,de Braud Filippo⁸,de Villambrosia Sonia Gonzalez⁹,Martin‐Romano Patricia¹,Baudin Eric¹¹⁰,Arias Marina¹¹,de Alvaro Juan¹¹,Parra‐Palau Josep L.¹¹,Sánchez‐Pérez Tania¹¹,Aronchik Ida¹²,Filvaroff Ellen H.¹²,Lamba Manisha¹²,Nikolova Zariana¹¹,de Bono Johann S.¹³

Affiliation:

1. Gustave Roussy Département d'innovation thérapeutique et essais précoces Villejuif France

2. S. Orsola Polyclinic Malpighi University Hospital Bologna Italy

3. Clinical and Translational Research Institute Northern Newcastle University Newcastle UK

4. Department of Medical Oncology ENETS Center of Excellence IPC NET Center Institut Paoli‐Calmettes Marseille France

5. Vall d'Hebron Institute of Oncology Vall d'Hebron University Hospital IOB‐Teknon Barcelona Spain

6. European Institute of Oncology, IRCCS, University of Milan Milan Italy

7. START Center for Cancer Care Jimenez Diaz University Hospital Madrid Spain

8. National Cancer Institute Milan Italy

9. Department of Hematology Hospital Universitario Marqués de Valdecilla/IDIVAL Santander Spain

10. Gustave Roussy Département D'oncologie Endocrinienne Villejuif France

11. Center for Innovation and Translational Research Europe A Bristol Myers Squibb Company Seville Spain

12. Bristol Myers Squibb Princeton New Jersey USA

13. The Institute of Cancer Research and Royal Marsden Hospital London UK

Funder

Bristol-Myers Squibb Canada

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34366

Reference47 articles.

1. Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1

2. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription

3. The Lysine-specific Demethylase 1 Is Required for Cell Proliferation in Both p53-dependent and -independent Manners

4. Histone demethylases in chromatin biology and beyond

5. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer;Journal of Medicinal Chemistry;2024-09-12

2. Targeting LSD1 in cancer: Molecular elucidation and recent advances;Cancer Letters;2024-08

3. Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer;Clinical Cancer Research;2024-04-17

4. Histone demethylase KDM1A promotes hepatic steatosis and inflammation by increasing chromatin accessibility in NAFLD;Journal of Lipid Research;2024-03

5. Advances in the treatment of relapsed/refractory marginal zone lymphoma;Frontiers in Oncology;2024-01-25